Design and development of a proniosomal transdermal drug delivery system of caffeine for management of migraine: In vitro characterization, 131I-radiolabeling and in vivo biodistribution studies

Caffeine is a naturally occurring alkaloid compound which is widely used alone or in combination in the treatment of migraine. The short elimination half life of caffeine (3−5 h) and the relationship between its absorption from gastrointestinal tract and gastric emptying are the major obstacles toward its effective oral delivery. To surmount such limitations, transdermal proniosomal systems of caffeine were developed. A full 3² factorial design was employed using Design-Expert® software to study the effect of different parameters and to select the optimal proniosomal system (PNS-4). Skin irritation study and in vivo histopathological examination confirmed the safety of transdermal application of PNS-4. Radioiodination of caffeine using iodine-131 (¹³¹I) was performed via direct electrophilic substitution reaction. Insilco docking results showed almost the same binding affinity of caffeine and ¹³¹I-Caffeine against adenosine A_2A receptor. Biodistribution results showed that, transdermal ¹³¹I-Caffeine loaded PNS-4 (patch) significantly increased the residence of ¹³¹I-Caffeine in the blood with higher brain targeting than oral suspension. The obtained results proved that, PNS-4 represents a promising transdermal drug delivery system capable of overcoming challenges facing oral delivery of caffeine.